Boxer Capital Management LLC Invests $4.45 Million in Celcuity, Inc. $CELC

Boxer Capital Management LLC purchased a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) during the third quarter, Holdings Channel reports. The fund purchased 90,000 shares of the company’s stock, valued at approximately $4,446,000. Celcuity accounts for approximately 1.4% of Boxer Capital Management LLC’s investment portfolio, making the stock its 18th largest position.

Other large investors have also recently bought and sold shares of the company. Ogorek Anthony Joseph NY ADV acquired a new position in Celcuity during the third quarter worth $27,000. US Bancorp DE lifted its position in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after buying an additional 143 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after acquiring an additional 1,167 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Celcuity by 211.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock worth $74,000 after acquiring an additional 3,766 shares in the last quarter. Finally, Avanza Fonder AB acquired a new position in shares of Celcuity during the 3rd quarter valued at about $79,000. 63.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. HC Wainwright reissued a “neutral” rating and issued a $94.00 price objective (up from $77.00) on shares of Celcuity in a research note on Monday, November 17th. Needham & Company LLC increased their price target on Celcuity from $95.00 to $122.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Jefferies Financial Group lifted their price target on shares of Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a research report on Tuesday, December 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, January 21st. Finally, Wolfe Research reaffirmed an “outperform” rating and set a $110.00 price objective on shares of Celcuity in a report on Thursday. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $108.63.

Celcuity Price Performance

NASDAQ CELC opened at $114.22 on Friday. Celcuity, Inc. has a twelve month low of $7.57 and a twelve month high of $120.32. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26. The stock has a market capitalization of $5.28 billion, a PE ratio of -31.12 and a beta of 0.38. The stock has a 50-day simple moving average of $108.80 and a 200 day simple moving average of $87.09.

Insider Buying and Selling

In other Celcuity news, Director David Dalvey sold 20,000 shares of Celcuity stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the transaction, the director directly owned 90,000 shares of the company’s stock, valued at $10,802,700. The trade was a 18.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 15.77% of the stock is currently owned by corporate insiders.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.